- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| AVICENA Aktie jetzt für 0€ handeln | |||||
| 12.03. | Avicena Tech Corp.: Avicena Launches the World's First microLED Optical Interconnect Evaluation Kit for AI Infrastructure Innovators | 578 | Business Wire | LightBundle eKit will demonstrate 512 Gbps links at OFC 2026
Avicena, the pioneer in microLED-based optical interconnects, today announced the LightBundle eKit, the industry's first evaluation... ► Artikel lesen | |
| 01.12.25 | Avicena's LightBundle optical links operating at 4Gbps per lane with transmitter current as low as 100µA per LED | 2 | Semiconductor Today | ||
| 17.11.25 | Avicena Advances microLED and Photo Detector Arrays to Enable the World's Lowest-Power AI Scale-up Optical Interconnects | 361 | Business Wire | Latest Avicena LightBundle technology delivers industry-leading Tx power of 80fJ/bit addressing next generation AI infrastructure requirements
Avicena, the leader in next-generation microLED interconnects... ► Artikel lesen | |
| 29.09.25 | Avicena Tech Corp.: Avicena Demonstrates Breakthrough Ultra-Low Power microLED Link at 200fJ/bit Tx Power | 352 | Business Wire | Avicena Is Showcasing an Ultra-low Power microLED Interconnect at 200fJ/bit of Transmitter Power Using Optimized Camera Sensor as the Receiver
Avicena, the leader in next-generation microLED interconnects... ► Artikel lesen | |
| 03.09.25 | Avicena Names Marco Chisari as New CEO | 541 | Business Wire | Amid unprecedented demand for ultra-low power optical interconnects in AI datacenters and future disaggregated memory fabrics, Avicena is poised for the next phase of growth
Avicena, the leader... ► Artikel lesen | |
| 14.05.25 | AvicenaTech, Corp.: Avicena Announces Series B Funding Round Led by Tiger Global with Participation from SK hynix | 1.106 | Business Wire | Amid unprecedented demand for ultra-low power optical interconnects in AI datacenters and future disaggregated memory fabrics, Avicena is preparing for the next phase of growth
Avicena, the leader... ► Artikel lesen | |
| 22.04.25 | Avicena Works with TSMC to Enable PD Arrays for LightBundle MicroLED-Based Interconnects | 617 | Business Wire | Avicena is working with TSMC to optimize silicon photodetector (PD) arrays for Avicena's LightBundle microLED-based interconnects aimed at AI scale-up networks with 1Tbps/mm I/O density and 1pJ/bit... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CG ONCOLOGY | 70,40 | -4,14 % | CG Oncology-Aktie erreicht Rekordhoch von 72,29 US-Dollar | ||
| KYMERA THERAPEUTICS | 86,93 | -0,82 % | Kymera Therapeutics, Inc.: Kymera Therapeutics Announces U.S. FDA Fast Track Designation for KT-621, a First-in-Class, Oral STAT6 Degrader for the Treatment of Moderate to Severe Asthma | KT-621 BREADTH Phase 2b asthma trial ongoing, with data expected to be reported in late 2027 KT-621 BROADEN2 Phase 2b atopic dermatitis (AD) trial ongoing, with data expected by mid-2027 Fast Track... ► Artikel lesen | |
| QIAGEN | 34,950 | -1,13 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 58 auf 44 Dollar gesenkt, aber die Aktie von "Overweight" auf "Equal Weight" abgestuft. Eine Übernahme... ► Artikel lesen | |
| DISC MEDICINE | 71,41 | -0,45 % | Disc Medicine Inc: Disc Medicine Announces Completion of Enrollment of Phase 3 APOLLO Trial of Bitopertin in Erythropoietic Protoporphyria | Last participant has been randomized and dosed in the Phase 3 APOLLO study of bitopertin in erythropoietic protoporphyria (EPP)The study size was expanded to 183 participants due to patient and physician... ► Artikel lesen | |
| VERA THERAPEUTICS | 41,610 | -1,58 % | Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer | BRISBANE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA), a biotechnology company focused on developing and commercializing transformative treatments for patients... ► Artikel lesen | |
| OLEMA PHARMACEUTICALS | 16,580 | -1,31 % | Olema Oncology Announces Preclinical Data for Palazestrant and OP-3136 at the 2026 AACR Annual Meeting | ||
| BIONTECH | 89,05 | -0,06 % | Hebel-Idee | Long-Chance: Statt BioNTech oder Evotec könnte jetzt diese Biotech-Aktie eine Rallye zünden! | © Foto: Gorodenkoff / Stock.adobe.comBei der Aktie von Illumina läuft ein Turnaround auf Mehrjahresebene. Nach einer Konsolidierung besteht für Anleger jetzt wieder die Chance zum Einstieg. Willkommen... ► Artikel lesen | |
| ERASCA | 21,700 | 0,00 % | Jefferies reiterates Erasca stock Buy rating ahead of ASCO data | ||
| ENVERIC BIOSCIENCES | 3,575 | 0,00 % | Enveric BioSciences Surges Over 90%, Other Psychedelic Stocks Soar In Monday Pre-Market: What's Going On? | ||
| PSYENCE BIOMEDICAL | 11,210 | 0,00 % | Psyence Biomedical Ltd.: Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine | NEW YORK, April 17, 2026 (GLOBE NEWSWIRE) -- Psyence Biomedical Ltd. (Nasdaq: PBM) ("Psyence BioMed" or the "Company"), a clinical-stage biopharmaceutical company advancing nature-derived psilocybin... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 46,410 | -3,44 % | Enliven Therapeutics (ELVN) Up 194% This Year on Strong CML Market | ||
| HARMONY BIOSCIENCES | 29,530 | -1,53 % | Dravet-Syndrom: Harmony Biosciences präsentiert neue Studiendaten | ||
| EVOTEC | 5,440 | -3,55 % | Evotec: Aktie profitiert von Kaufempfehlung | Die Aktie von Evotec legt heute um mehr als sechs Prozent zu. Die Privatbank Berenberg sieht in der konsequenten Integration von Künstlicher Intelligenz einen entscheidenden Wachstumstreiber bei Evotec... ► Artikel lesen | |
| ARRIVENT BIOPHARMA | 31,390 | +6,08 % | ArriVent BioPharma, Inc.: ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer | Firmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 25,120 | 0,00 % | UBS reiterates Buy on Summit Therapeutics stock ahead of trial data |
Das Unternehmen AVICENA GROUP INC kann der Branche Biotechnologie zugeordnet werden.
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu AVICENA GROUP INC finden Sie auf Wallstreet Online.